Title: Relationship Between Gastric Mucosal Atrophy, Cystic Dilatation, and Histopathological
Characteristics
Version: 2 Date: 19 Dec 2024
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-Consider adding a short explanation of the key histological terms and their significance in the
context of gastric cancer progression (e.g., what non-intestinal metaplasia refers to and how it
differs from intestinal metaplasia).
-The connection between cystic dilatation and gastric cancer progression is an important aspect
of the study, but the introduction could do more to explain how cystic dilatation is a precursor
or intermediate stage in this progression. For instance, what specific histopathological features
distinguish cystic dilatation from other forms of mucosal atrophy, and how do these features
correlate with malignant potential?
-Cite additional studies focusing on the morphologic and histological features of cystic
dilatation, to reinforce the novelty and relevance of the current study's objectives.
-The discussion outlines several contributing factors (infection, immune response, genetic
influences) but does not go into detail about the precise molecular mechanisms responsible for
the development of cystic dilatation. For example, how do these factors lead to the specific
histopathological changes observed in the gastric mucosa? Are there specific genetic mutations
or signaling pathways that drive the transformation from atrophy to cystic dilatation?
-Provide a more in-depth explanation of how the histopathological features of cystic dilatation
correlate with specific types of early gastric cancer. What key changes (e.g., cellular atypia,
invasion) are observed in cystic dilatation lesions that could predict progression to papillary
cystadenocarcinoma or other types of gastric cancer?
-Offer more concrete suggestions for clinicians on how to manage patients with gastric mucosal
cystic dilatation. For instance, should patients with compound cystic dilatation undergo more
frequent surveillance, or should early intervention strategies be considered?
Title: Relationship Between Gastric Mucosal Atrophy, Cystic Dilatation, and Histopathological
Characteristics
Version: 2 Date: 19 Dec 2024
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-Consider adding a short explanation of the key histological terms and their significance in the
context of gastric cancer progression (e.g., what non-intestinal metaplasia refers to and how it
differs from intestinal metaplasia).
-The connection between cystic dilatation and gastric cancer progression is an important aspect
of the study, but the introduction could do more to explain how cystic dilatation is a precursor
or intermediate stage in this progression. For instance, what specific histopathological features
distinguish cystic dilatation from other forms of mucosal atrophy, and how do these features
correlate with malignant potential?
-Cite additional studies focusing on the morphologic and histological features of cystic
dilatation, to reinforce the novelty and relevance of the current study's objectives.
-The discussion outlines several contributing factors (infection, immune response, genetic
influences) but does not go into detail about the precise molecular mechanisms responsible for
the development of cystic dilatation. For example, how do these factors lead to the specific
histopathological changes observed in the gastric mucosa? Are there specific genetic mutations
or signaling pathways that drive the transformation from atrophy to cystic dilatation?
-Provide a more in-depth explanation of how the histopathological features of cystic dilatation
correlate with specific types of early gastric cancer. What key changes (e.g., cellular atypia,
invasion) are observed in cystic dilatation lesions that could predict progression to papillary
cystadenocarcinoma or other types of gastric cancer?
-Offer more concrete suggestions for clinicians on how to manage patients with gastric mucosal
cystic dilatation. For instance, should patients with compound cystic dilatation undergo more
frequent surveillance, or should early intervention strategies be considered?
Please review this paper.
user
Title: Relationship Between Gastric Mucosal Atrophy, Cystic Dilatation, and Histopathological
Characteristics
Version: 2 Date: 19 Dec 2024
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-Consider adding a short explanation of the key histological terms and their significance in the
context of gastric cancer progression (e.g., what non-intestinal metaplasia refers to and how it
differs from intestinal metaplasia).
-The connection between cystic dilatation and gastric cancer progression is an important aspect
of the study, but the introduction could do more to explain how cystic dilatation is a precursor
or intermediate stage in this progression. For instance, what specific histopathological features
distinguish cystic dilatation from other forms of mucosal atrophy, and how do these features
correlate with malignant potential?
-Cite additional studies focusing on the morphologic and histological features of cystic
dilatation, to reinforce the novelty and relevance of the current study's objectives.
-The discussion outlines several contributing factors (infection, immune response, genetic
influences) but does not go into detail about the precise molecular mechanisms responsible for
the development of cystic dilatation. For example, how do these factors lead to the specific
histopathological changes observed in the gastric mucosa? Are there specific genetic mutations
or signaling pathways that drive the transformation from atrophy to cystic dilatation?
-Provide a more in-depth explanation of how the histopathological features of cystic dilatation
correlate with specific types of early gastric cancer. What key changes (e.g., cellular atypia,
invasion) are observed in cystic dilatation lesions that could predict progression to papillary
cystadenocarcinoma or other types of gastric cancer?
-Offer more concrete suggestions for clinicians on how to manage patients with gastric mucosal
cystic dilatation. For instance, should patients with compound cystic dilatation undergo more
frequent surveillance, or should early intervention strategies be considered?
assistant